Isaac S. Ashkenazi is a partner in the Life Sciences IP group of Paul Hastings and is based in the firm's New York office. He focuses his practice on complex intellectual property disputes primarily in the pharmaceutical, chemistry and biotechnology fields.

He has successfully represented some of the world’s leading life sciences companies in high-stakes patent disputes involving their critical drug products in various forums, including the PTAB, ITC, district courts, appeals courts and arbitrations. Isaac has experience with a broad range of technologies, including pharmaceutical compounds, proteins, antibodies, ADCs, polymers, formulations and chemical and synthetic processes, as well as a wide variety of therapeutics, including oncology drugs, Parkinson’s medications, proton pump inhibitors, sleep agents, respiratory agents, antiemetics, alcohol and opioid dependence treatments and cholesterol-lowering and antidiabetic agents.

• Chambers USA, Intellectual Property: Patent (2024)
• IAM Patent 1000, Leading Patent Professional (2022-2024)
• Managing Intellectual Property, IP Star (2023)
• The Legal 500's Intellectual Property - Patents: Litigation (Full Coverage) (2021, 2023)
• Law360, Rising Star in Life Sciences, 2018 -- for several high-stakes wins, including invalidating a key patent for Humira®, the world’s best-selling drug
• Recognized in The Legal 500 for two successful IPR petitions resulting in rulings that method-of-treatment claims covering the drug product Humira® would have been obvious
• American Lawyer, Transatlantic IP Team of the Year, 2018 -- for leading a major pharmaceutical litigation through fact, expert and Markman phases, and obtaining six walk-away consent judgments
• Law360, Life Sciences Practice Group of the Year, 2017
• Law360, Two-Time Legal Lion

• Benjamin N. Cardozo School of Law, J.D. (concentration in Intellectual Property), 2005
• The Cooper Union, B.E.C.E., 2002